A lung cancer study showed that KAS mutations drive ACSL3 expression, thereby promoting fatty acid absorption, retention, accumulation, and beta-oxidation in cancer cells, and identified ACSL3 as a potential metabolic therapeutic target [20]. Here, ACSL3 is linked to lung carcinoma.